1. |
Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012, 367: 1332-1340.
|
2. |
Heise T, Zijlstra E, Nosek L, et al. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab, 2016, 18(10): 962-972.
|
3. |
Andres R, Baltzan MA, Cader G, et al. Effect of insulin on carbohydrate metabolism and on potassium in the forearm of man. J Clin Invest, 1962, 41(1): 108-115.
|
4. |
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237(3): E214-E223.
|
5. |
邓尚平. 胰岛素抵抗的临床测定方法和评价//李秀钧. 代谢综合征. 2 版. 北京: 人民卫生出版社, 2007: 101-109.
|
6. |
董立厚, 宋海峰. 高胰岛素-正葡萄糖钳夹技术的研究进展. 中国新药杂志, 2007, 16(19): 1561-1564.
|
7. |
Huang M, Joseph JW. Assessment of the metabolic pathways associated with glucose-stimulated biphasic insulin secretion. Endocrinology, 2014, 155(5): 1653-1666.
|
8. |
Donga E, Dekkers OM, Corssmit EP, et al. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015, 173(1): 101-109.
|
9. |
赵维纲, 袁涛, 付勇, 等. 正常血糖高胰岛素钳夹法观察罗格列酮治疗 2 型糖尿病胰岛素抵抗的疗效. 中华临床营养杂志, 2009, 17(3): 133-135.
|
10. |
Rave K, Nosek L, Heinemann L, et al. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Diabetes Metab, 2003, 29(4 Pt 1): 430-431.
|
11. |
赵维纲, 王姮, 李玉秀, 等. 胰岛素口腔喷雾剂在正常人口腔粘膜的吸收和生物学效应. 中华内分泌代谢杂志, 2003, 19(4): 275-278.
|
12. |
Becker RH, Frick AD, Burger F, et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes, 2005, 113(5): 292-297.
|
13. |
Scholtz HE, Pretorius SG, Wessels DH, et al. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia, 2005, 48(10): 1988-1995.
|
14. |
Hompesch M, Ocheltree SM, Wondmagegnehu ET, et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin, 2009, 25(11): 2679-2687.
|
15. |
Benesch C, Heise T, Klein O, et al. How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device. J Diabetes Sci Technol, 2015, 9(4): 792-800.
|
16. |
Cahn A, Miccoli R, Dardano A, et al. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol, 2015, 3(8): 638-652.
|
17. |
De Souza AL, Batista GA, Alegre SM. Assessment of insulin sensitivity by the hyperinsulinemic euglycemic clamp: comparison with the spectral analysis of photoplethysmography. J Diabetes Complications, 2017, 31(1): 128-133.
|
18. |
廖志红, 廖瑛, 李延兵, 等. 吸入胰岛素粉雾剂对 1 型糖尿病患者药代学的一期临床研究. 中华医学杂志, 2006, 86(28): 2005-2007.
|
19. |
程时武, 陆菊明, 潘长玉, 等. 重组甘精胰岛素注射液的人体药代动力学、药效学及生物等效性研究. 中国糖尿病杂志, 2010, 18(5): 387-391.
|
20. |
谭惠文, 王椿, 刘瑶霞, 等. 短效重组人胰岛素在人体内的药动学及药效学研究. 华西药学杂志, 2011, 26(5): 430-434.
|
21. |
Li J, Wang Y, Han L, et al. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. Clin Ther, 2012, 34(12):2333-2338.
|
22. |
Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab, 2014, 16 (1): 57-62.
|
23. |
Heise T, Hövelmann U, Nosek L, et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol, 2015, 11(8):1193-1201.
|
24. |
Linnebjerg H, Lam EC, Zhang X, et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes Metab, 2017, 19(1): 33-39.
|
25. |
Kapitza C, Nowotny I, Lehmann A, et al. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes Obes Metab, 2017, 19(5): 622-627.
|
26. |
Setji TL, Hong BD, Feinglos MN. Technosphere insulin: inhaled prandial insulin. Expert Opin Biol Ther, 2016, 16(1): 111-117.
|